Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. Some of the key highlights related to atopic dermatitis (AD) therapies include:

APG777

APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13. APG777 demonstrates a 77-day half-life in a 12-month update from the Phase 1 study in healthy volunteers. Single doses of APG777 led to prolonged signal transducer and activator of transcription 6 (pSTAT6) inhibition for up to 12 months and deeper, more sustained thymus and activation-regulated chemokine (TARC) reduction. A two-part Phase 2 study of APG777 in adults with moderate-to-severe AD is currently underway; 16-week results of Part A are now anticipated in mid-2025, based on strong enrollment to date.

APG777 and APG990

The combination of APG777  and APG990, an optimized anti-OX40L mAb has been shown to retain stability, injectability, and convenience of individual components. In preclinical studies, APG777 and APG990 have demonstrated broad inhibition of Type 1, Type 2, and Type 3 inflammation. Pending APG990’s Phase 1 results, which are expected in the first half of 2025, Apogee plans to initiate its first combination trial in 2025 – a Phase 1b trial designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the combination of APG777 and APG990 versus dupilumab in ~50-75 patients with moderate-to-severe AD, with data expected in the second half of 2026.

Stay tuned.